Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Armuzzi

Showing results (151-160 of 320) with videos related to

Pageof 32
Sort By:
Digestive Diseases (Basel, Switzerland)|January 5, 2023
Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE ProgramMarla C Dubinsky, Alessandro Armuzzi, Krisztina B Gecse, et al.
Inflammatory Bowel Diseases|September 2, 2020
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient ManagementBruce E Sands, Jean-Frédéric Colombel, Christina Ha, et al.
Inflammatory Bowel Diseases|July 6, 2022
Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis ProgramEdward V Loftus, Daniel C Baumgart, Krisztina Gecse, et al.
Frontiers in Immunology|August 20, 2025
Digital biomarkers and artificial intelligence: a new frontier in personalized management of inflammatory bowel diseaseDiletta De Deo, Arianna Dal Buono, Roberto Gabbiadini, et al.
Journal of Clinical Medicine|July 27, 2024
Eosinophils, Eosinophilic Gastrointestinal Diseases, and Inflammatory Bowel Disease: A Critical ReviewGiulia Migliorisi, Elisabetta Mastrorocco, Arianna Dal Buono, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 3, 2023
Exploring the link: Porto-sinusoidal vascular disorder and inflammatory bowel disease - A comprehensive narrative reviewNicola Pugliese, Lucia Giuli, Elisabetta Mastrorocco, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 24, 2023
Nutritional care at centres managing patients with inflammatory bowel disease: A nationwide survey in ItalySimone Saibeni, Michela Zanetti, Cristina Bezzio, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 13, 2021
Histopathology of non-IBD colitis practical recommendations from pathologists of IG-IBD GroupLuca Reggiani Bonetti, Giuseppe Leoncini, Marco Daperno, et al.
Journal of Crohn'S & Colitis|April 3, 2012
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agentsAlfredo Papa, Carla Felice, Manuela Marzo, et al.
Plos One|March 14, 2017
The miR-200 family is increased in dysplastic lesions in ulcerative colitis patientsAmy Lewis, Carla Felice, Tomoko Kumagai, et al.
Pageof 32

Showing results (151-160 of 320) with videos related to

Sort By:
Pageof 32
Digestive Diseases (Basel, Switzerland)|January 5, 2023
Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE ProgramMarla C Dubinsky, Alessandro Armuzzi, Krisztina B Gecse, et al.
Inflammatory Bowel Diseases|September 2, 2020
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient ManagementBruce E Sands, Jean-Frédéric Colombel, Christina Ha, et al.
Inflammatory Bowel Diseases|July 6, 2022
Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis ProgramEdward V Loftus, Daniel C Baumgart, Krisztina Gecse, et al.
Frontiers in Immunology|August 20, 2025
Digital biomarkers and artificial intelligence: a new frontier in personalized management of inflammatory bowel diseaseDiletta De Deo, Arianna Dal Buono, Roberto Gabbiadini, et al.
Journal of Clinical Medicine|July 27, 2024
Eosinophils, Eosinophilic Gastrointestinal Diseases, and Inflammatory Bowel Disease: A Critical ReviewGiulia Migliorisi, Elisabetta Mastrorocco, Arianna Dal Buono, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 3, 2023
Exploring the link: Porto-sinusoidal vascular disorder and inflammatory bowel disease - A comprehensive narrative reviewNicola Pugliese, Lucia Giuli, Elisabetta Mastrorocco, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 24, 2023
Nutritional care at centres managing patients with inflammatory bowel disease: A nationwide survey in ItalySimone Saibeni, Michela Zanetti, Cristina Bezzio, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 13, 2021
Histopathology of non-IBD colitis practical recommendations from pathologists of IG-IBD GroupLuca Reggiani Bonetti, Giuseppe Leoncini, Marco Daperno, et al.
Journal of Crohn'S & Colitis|April 3, 2012
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agentsAlfredo Papa, Carla Felice, Manuela Marzo, et al.
Plos One|March 14, 2017
The miR-200 family is increased in dysplastic lesions in ulcerative colitis patientsAmy Lewis, Carla Felice, Tomoko Kumagai, et al.
Pageof 32